Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 5/20 | 0.36 |
| ▸ | KDR | P35968 | 5/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13889495 | 1.00 | POLB (0.37) | POLBALDH1A1SMN1; SMN2MAPK1RET | |
| SCHEMBL12601698 | 0.93 | POLB (0.38) | POLBALDH1A1SMN1; SMN2MAPK1RET | |
| SCHEMBL13889497 | 0.93 | POLB (0.38) | POLBALDH1A1SMN1; SMN2MAPK1RET | |
| SCHEMBL889922 | 0.89 | SMN1; SMN2 (0.36) | POLBALDH1A1SMN1; SMN2MAPK1RET | |
| SCHEMBL889888 | 0.82 | RET (0.37) | POLBALDH1A1SMN1; SMN2MAPK1RET | |
| SCHEMBL13889496 | 0.82 | ALDH1A1 (0.43) | POLBALDH1A1SMN1; SMN2MAPK1RET | |
| SCHEMBL26298205 | 0.82 | ALDH1A1 (0.43) | POLBALDH1A1SMN1; SMN2MAPK1RET | |
| SCHEMBL12601699 | 0.82 | ALDH1A1 (0.43) | POLBALDH1A1SMN1; SMN2MAPK1RET | |
| SCHEMBL12601712 | 0.76 | ADK (0.48) | RETKDRSIGMAR1 | |
| SCHEMBL26298301 | 0.76 | ADK (0.48) | RETKDRSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943752-B2 | Modified oligonucleotides and applications thereof | Applied Biosystems, L.L.C. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090226924-A1 | Modified Oligonucleotides and Applications Thereof | APPLERA CORPORATION | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226924-A1 | Modified Oligonucleotides and Applications Thereof | RNGTT, POLRMT, POLM | POLB 8/4885ALDH1A1 3067/4885SMN1; SMN2 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.